Literature DB >> 24845581

Effective glycaemic control critically determines insulin cardioprotection against ischaemia/reperfusion injury in anaesthetized dogs.

Qiujun Yu1, Ning Zhou2, Ying Nan3, Lihua Zhang4, Yan Li1, Xiaoke Hao5, Lize Xiong6, Wayne Bond Lau7, Xin L Ma7, Haichang Wang8, Feng Gao9.   

Abstract

AIMS: Experimental evidence has shown significant cardioprotective effects of insulin, whereas clinical trials produced mixed results without valid explanations. This study was designed to examine the effect of hyperglycaemia on insulin cardioprotective action in a preclinical large animal model of myocardial ischaemia/reperfusion (MI/R). METHODS AND
RESULTS: Anaesthetized dogs were subjected to MI/R (30 min/4 h) and randomized to normal plasma insulin/euglycaemia (NI/NG), normal-insulin/hyperglycaemia (NI/HG), high-insulin/euglycaemia (HI/NG), and high-insulin/hyperglycaemia (HI/HG) achieved by controlled glucose/insulin infusion. Endogenous insulin production was abolished by peripancreatic vessel ligation. Compared with the control animals (NI/NG), hyperglycaemia (NI/HG) significantly aggravated MI/R injury. Insulin elevation at clamped euglycaemia (HI/NG) protected against MI/R injury as evidenced by reduced infarct size, decreased necrosis and apoptosis, and alleviated inflammatory and oxidative stress (leucocyte infiltration, myeloperoxidase, and malondialdehyde levels). However, these cardioprotective effects of insulin were markedly blunted in hyperglycaemic animals (HI/HG). In vitro mechanistic study in neonatal rat cardiomyocytes revealed that insulin-stimulated tyrosine phosphorylation of insulin receptor substrate-1 (IRS-1) and Akt was significantly attenuated by high glucose, accompanied by markedly increased IRS-1 O-GlcNAc glycosylation following hypoxia/reoxygenation. Inhibition of hexosamine biosynthesis with 6-diazo-5-oxonorleucine abrogated high glucose-induced O-GlcNAc modification and inactivation of IRS-1/Akt as well as cell injury.
CONCLUSIONS: Our results, derived from a canine model of MI/R, demonstrate that hyperglycaemia blunts insulin protection against MI/R injury via hyperglycaemia-induced glycosylation and subsequent inactivation of insulin-signalling proteins. Our findings suggest that prevention of hyperglycaemia is critical for achieving maximal insulin cardioprotection for the ischaemic/reperfused hearts. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2014. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardioprotection; Dog; Hyperglycaemia; Insulin; Myocardial ischaemia/reperfusion

Mesh:

Substances:

Year:  2014        PMID: 24845581     DOI: 10.1093/cvr/cvu132

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  14 in total

Review 1.  Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols.

Authors:  Claudia Penna; Ioanna Andreadou; Manuela Aragno; Christophe Beauloye; Luc Bertrand; Antigone Lazou; Ines Falcão-Pires; Robert Bell; Coert J Zuurbier; Pasquale Pagliaro; Derek J Hausenloy
Journal:  Br J Pharmacol       Date:  2020-03-09       Impact factor: 8.739

2.  Down-regulation of Insulin Receptor Substrate 1 during Hyperglycemia Induces Vascular Smooth Muscle Cell Dedifferentiation.

Authors:  Gang Xi; Christine Wai; Morris F White; David R Clemmons
Journal:  J Biol Chem       Date:  2016-12-21       Impact factor: 5.157

Review 3.  O-GlcNAcylation and cardiovascular disease.

Authors:  JaLessa N Wright; Helen E Collins; Adam R Wende; John C Chatham
Journal:  Biochem Soc Trans       Date:  2017-04-15       Impact factor: 5.407

4.  Mutual inhibition of insulin signaling and PHLPP-1 determines cardioprotective efficiency of Akt in aged heart.

Authors:  Yuan Xing; Wanqing Sun; Yishi Wang; Feng Gao; Heng Ma
Journal:  Aging (Albany NY)       Date:  2016-05       Impact factor: 5.682

5.  Direct Evidence that Myocardial Insulin Resistance following Myocardial Ischemia Contributes to Post-Ischemic Heart Failure.

Authors:  Feng Fu; Kun Zhao; Jia Li; Jie Xu; Yuan Zhang; Chengfeng Liu; Weidong Yang; Chao Gao; Jun Li; Haifeng Zhang; Yan Li; Qin Cui; Haichang Wang; Ling Tao; Jing Wang; Michael J Quon; Feng Gao
Journal:  Sci Rep       Date:  2015-12-14       Impact factor: 4.379

6.  Glycemia and the cardioprotective effects of insulin pre-conditioning in the isolated rat heart.

Authors:  Yosuke Nakadate; Hiroaki Sato; Takeshi Oguchi; Tamaki Sato; Akiko Kawakami; Tadahiko Ishiyama; Takashi Matsukawa; Thomas Schricker
Journal:  Cardiovasc Diabetol       Date:  2017-04-04       Impact factor: 9.951

Review 7.  Myocyte membrane and microdomain modifications in diabetes: determinants of ischemic tolerance and cardioprotection.

Authors:  Jake Russell; Eugene F Du Toit; Jason N Peart; Hemal H Patel; John P Headrick
Journal:  Cardiovasc Diabetol       Date:  2017-12-04       Impact factor: 9.951

8.  An MG53-IRS1-interaction disruptor ameliorates insulin resistance.

Authors:  Jun Sub Park; Hyun Lee; Bo Woon Choi; Seonggu Ro; Doyoung Lee; Jeong Eun Na; Jeoung-Ho Hong; Jae-Seon Lee; Bong-Woo Kim; Young-Gyu Ko
Journal:  Exp Mol Med       Date:  2018-06-06       Impact factor: 8.718

9.  Mst1 inhibits CMECs autophagy and participates in the development of diabetic coronary microvascular dysfunction.

Authors:  Jie Lin; Lei Zhang; Mingming Zhang; Jianqiang Hu; Tingting Wang; Yu Duan; Wanrong Man; Bin Wu; Jiaxu Feng; Lei Sun; Congye Li; Rongqing Zhang; Haichang Wang; Dongdong Sun
Journal:  Sci Rep       Date:  2016-09-29       Impact factor: 4.379

10.  Modified Glucose-Insulin-Potassium Regimen Provides Cardioprotection With Improved Tissue Perfusion in Patients Undergoing Cardiopulmonary Bypass Surgery.

Authors:  Kun Zhao; Yue Zhang; Jia Li; Qin Cui; Rong Zhao; Wensheng Chen; Jincheng Liu; Bijun Zhao; Yi Wan; Xin-Liang Ma; Shiqiang Yu; Dinghua Yi; Feng Gao
Journal:  J Am Heart Assoc       Date:  2020-03-10       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.